

RESU TS REC P ENT

SEATTLE SPERM BANK

Attn: Jeffrey Olliffe 4915 25th Ave NE Ste 204w Seattle, WA 98105-5668 Phone: (206) 588-1484 Fax: (206) 466-4696 NPI: 1306838271

Report Date: 08/02/2019

DONOR 10379 DOB:

MA E

Ethnicity: Northern European Sample Type: EDTA Blood Date of Collection: 07/26/2019 Date Received: 07/27/2019 Date Tested: 08/02/2019 Barcode: 11004212607604 Accession ID: CSL3HAZKZ9D4RJQ Indication: Egg or sperm donor FEMA E N/A

Foresight® Carrier Screen

NEGATIVE

ABOUT THIS TEST

The **Myriad Foresight Carrier Screen** utilizes sequencing, maximizing coverage across all DNA regions tested, to help you learn about your chance to have a child with a genetic disease.

RESULTS SUMMARY

Risk Details	DONOR 10379	Partner	
Panel Information	Foresight Carrier Screen Universal Panel Fundamental Plus Panel Fundamental Panel (175 conditions tested)	N/A	
All conditions tested A complete list of all conditions tested can be found on page 4.	 □ NEGATIVE No disease-causing mutations we detected. 	N/A re	

CLINICAL NOTES

None

NEXT STEPS

• If necessary, patients can discuss residual risks with their physician or a genetic counselor.



MA E

DONOR 10379

DOB:

Ethnicity: Northern European Barcode: 11004212607604

FEMA E N/A

Methods and Limitations

DONOR 10379 [Foresight Carrier Screen]: Sequencing with copy number analysis, spinal muscular atrophy, and analysis of homologous regions.

Sequencing with copy number analysis

High-throughput sequencing and read depth-based copy number analysis are used to analyze the listed exons, as well as selected intergenic and intronic regions, of the genes in the Conditions Tested section of the report. The region of interest (ROI) of the test comprises these regions, in addition to the 20 intronic bases flanking each exon. In a minority of cases where genomic features (e.g., long homopolymers) compromise calling fidelity, the affected intronic bases are not included in the ROI. The ROI is sequenced to high coverage and the sequences are compared to standards and references of normal variation. More than 99% of all bases in the ROI are sequenced at greater than the minimum read depth. Mutations may not be detected in areas of lower sequence coverage. Small insertions and deletions may not be as accurately determined as single nucleotide variants. Genes that have closely related pseudogenes may be addressed by a different method. *CFTR* and *DMD* testing includes analysis for both large (exon-level) deletions and duplications with an average sensitivity of 99%, while other genes are only analyzed for large deletions with a sensitivity of >75%. However, the sensitivity may be higher for selected founder deletions. The breakpoints of copy number variants and exons affected are estimated from probe positions. Only exons known to be included in the copy number variant are provided in the name. In some cases, the copy number variant may be larger or smaller than indicated. If *GJB2* is tested, two large upstream deletions which overlap *GJB6* and affect the expression of *GJB2*, del(*GJB6*-D13S1830) and del(*GJB6*-D13S1854), are also analyzed. Mosaicism or somatic variants present at low levels may not be detected. If detected, these may not be reported.

Detection rates are determined by using literature to estimate the fraction of disease alleles, weighted by frequency, that the methodology is unable to detect. Detection rates only account for analytical sensitivity and certain variants that have been previously described in the literature may not be reported if there is insufficient evidence for pathogenicity. Detection rates do not account for the disease-specific rates of de novo mutations.

All variants that are a recognized cause of the disease will be reported. In addition, variants that have not previously been established as a recognized cause of disease may be identified. In these cases, only variants classified as "likely" pathogenic are reported. Likely pathogenic variants are described elsewhere in the report as "likely to have a negative impact on gene function". Likely pathogenic variants are evaluated and classified by assessing the nature of the variant and reviewing reports of allele frequencies in cases and controls, functional studies, variant annotation and effect prediction, and segregation studies. Exon level duplications are assumed to be in tandem and are classified according to their predicted effect on the reading frame. Benign variants, variants of uncertain significance, and variants not directly associated with the intended disease phenotype are not reported. Curation summaries of reported variants are available upon request.

Spinal muscular atrophy

Targeted copy number analysis is used to determine the copy number of exon 7 of the *SMN1* gene relative to other genes. Other mutations may interfere with this analysis. Some individuals with two copies of *SMN1* are carriers with two *SMN1* genes on one chromosome and a *SMN1* deletion on the other chromosome. This is more likely in individuals who have 2 copies of the *SMN1* gene and are positive for the g.27134T>G SNP, which affects the reported residual risk; Ashkenazi Jewish or Asian patients with this genotype have a high post-test likelihood of being carriers for SMA and are reported as carriers. The g.27134T>G SNP is only reported in individuals who have 2 copies of *SMN1*.

Analysis of homologous regions

A combination of high-throughput sequencing, read depth-based copy number analysis, and targeted genotyping is used to determine the number of functional gene copies and/or the presence of selected loss of function mutations in certain genes that have homology to other regions. The precise breakpoints of large deletions in these genes cannot be determined, but are estimated from copy number analysis. High numbers of pseudogene copies may interfere with this analysis.

If *CYP21A2* is tested, patients who have one or more additional copies of the *CYP21A2* gene and a loss of function mutation may not actually be a carrier of 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH). Because the true incidence of non-classic CAH is unknown, the residual carrier and reproductive risk numbers on the report are only based on published incidences for classic CAH. However, the published prevalence of non-classic CAH is highest in individuals of Ashkenazi Jewish, Hispanic, Italian, and Yugoslav descent. Therefore, the residual and reproductive risks are likely an underestimate of overall chances for 21-hydroxylase-deficient CAH, especially in the aforementioned populations, as they do not account for non-classic CAH. If *HBA11HBA2* are tested, some individuals with four alpha globin genes may be carriers, with three genes on one chromosome and a deletion on the other chromosome. This and similar, but rare, carrier states, where complementary changes exist in both the gene and a pseudogene, may not be detected by the assay.



MA E
DONOR 10379
DOB:

Ethnicity: Northern European Barcode: 11004212607604

FEMA E N/A

Limitations

In an unknown number of cases, nearby genetic variants may interfere with mutation detection. Other possible sources of diagnostic error include sample mix-up, trace contamination, bone marrow transplantation, blood transfusions and technical errors. This test is designed to detect and report germline alterations. While somatic variants present at low levels may be detected, these may not be reported. If more than one variant is detected in a gene, additional studies may be necessary to determine if those variants lie on the same chromosome or different chromosomes. The test does not fully address all inherited forms of intellectual disability, birth defects and genetic disease. A family history of any of these conditions may warrant additional evaluation. Furthermore, not all mutations will be identified in the genes analyzed and additional testing may be beneficial for some patients. For example, individuals of African, Southeast Asian, and Mediterranean ancestry are at increased risk for being carriers for hemoglobinopathies, which can be identified by CBC and hemoglobin electrophoresis or HPLC (ACOG Practice Bulletin No 78 Obstet Gynecol 2007;109 229-37).

This test was developed and its performance characteristics determined by Myriad Women's Health, Inc. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA does not require this test to go through premarket review. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These results are adjunctive to the ordering physician's evaluation. CLIA Number: #05D1102604.

Resources

GENOME CONNECT | http://www.genomeconnect.org

Patients can share their reports via research registries such as Genome Connect, an online research registry working to build the knowledge base about genetics and health. Genome Connect provides patients, physicians, and researchers an opportunity to share genetic information to support the study of the impact of genetic variation on health conditions.

SENIOR LABORATORY DIRECTOR

Jack Ji, PhD, FACMG

Salk 5

Report content approved by Lulu Mao, PhD, DABMGG on Aug 2, 2019



RESU TS REC P ENT
SEATTLE SPERM BANK
Attn: Jeffrey Olliffe
NPI: 1306838271

Attn: Jeffrey Olliffe DOB: |
NPI: 1306838271 Ethnic
Report Date: 08/02/2019 Barcoo

Ethnicity: Northern European Barcode: 11004212607604

MA E

DONOR 10379

FEMA E

Conditions Tested

11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia - Gene: CYP11B1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000497:1-9. **Detection Rate:** Northern European 94%.

6-pyruvoyl-tetrahydropterin Synthase Deficiency - **Gene:** PTS. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000317:1-6. **Detection Rate:** Northern European >99%.

ABCC8-related Familial Hyperinsulinism - **Gene**: ABCC8. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000352:1-39. **Detection Rate**: Northern European >99%.

Adenosine Deaminase Deficiency - Gene: ADA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000022:1-12. Detection Rate: Northern European >99%.

Alpha Thalassemia - **Genes**: HBA1, HBA2. Autosomal Recessive. Analysis of homologous regions. **Variants** (13): -(alpha)20 5, --BRIT, --MEDI, --MEDII, --SEA, -- THAI or --FIL, -alpha3.7, -alpha4.2, HBA1+HBA2 deletion, Hb Constant Spring, anti3.7, anti4.2, del HS-40. **Detection Rate**: Unknown due to rarity of disease.

Alpha-mannosidosis - **Gene**: MAN2B1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000528:1-23. **Detection Rate**: Northern European >99%.

Alpha-sarcoglycanopathy - **Gene:** SGCA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000023:1-9. **Detection Rate:** Northern European >99%

Alstrom Syndrome - **Gene**: ALMS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_015120:1-23. **Detection Rate**: Northern European >99%.

AMT-related Glycine Encephalopathy - **Gene**: AMT. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000481:1-9. **Detection Rate**: Northern European >99%.

Andermann Syndrome - **Gene:** SLC12A6. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_133647:1-25. **Detection Rate:** Northern European >99%.

Argininemia - **Gene**: ARG1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000045:1-8. **Detection Rate**: Northern European 97%.

Argininosuccinic Aciduria - **Gene:** ASL. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_001024943:1-16. **Detection Rate:** Northern European

Aspartylglucosaminuria - **Gene**: AGA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000027:1-9. **Detection Rate**: Northern European >99%

Ataxia with Vitamin E Deficiency - Gene: TTPA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000370:1-5. **Detection Rate:** Northern European >99%.

Ataxia-telangiectasia - Gene: ATM. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000051:2-63. Detection Rate: Northern European

ATP7A-related Disorders - **Gene**: ATP7A. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM_000052:2-23. **Detection Rate**: Northern European 96%.

Autoimmune Polyglandular Syndrome Type 1 - **Gene**: AIRE. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000383:1-14. **Detection Rate**: Northern European >99%.

Autosomal Recessive Osteopetrosis Type 1 - **Gene**: TCIRG1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_006019:2-20. **Detection Rate**: Northern European >99%.

Autosomal Recessive Polycystic Kidney Disease, PKHD1-related - **Gene**: PKHD1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_138694:2-67. **Detection Rate**: Northern European >99%.

Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay - **Gene:** SACS. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_014363:2-10. **Detection Rate:** Northern European 99%.

Bardet-Biedl Syndrome, BBS1-related - **Gene**: BBS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_024649:1-17. **Detection Rate**: Northern European >99%.

Bardet-Biedl Syndrome, BBS10-related - **Gene**: BBS10. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_024685:1-2. **Detection Rate**: Northern European >99%.

Bardet-Biedl Syndrome, BBS12-related - **Gene:** BBS12. Autosomal Recessive. Sequencing with copy number analysis. **Exon:** NM_152618:2. **Detection Rate:** Northern European >99%.

Bardet-Biedl Syndrome, BBS2-related - **Gene:** BBS2. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_031885:1-17. **Detection Rate:** Northern European >99%.

BCS1L-related Disorders - **Gene**: BCS1L. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_004328:3-9. **Detection Rate**: Northern European >99%.

Beta-sarcoglycanopathy - **Gene:** SGCB. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000232:1-6. **Detection Rate:** Northern European >99%.

Biotinidase Deficiency - **Gene:** BTD. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000060:1-4. **Detection Rate:** Northern European >99%

Bloom Syndrome - **Gene:** BLM. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000057:2-22. **Detection Rate:** Northern European >99%.

Calpainopathy - Gene: CAPN3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000070:1-24. Detection Rate: Northern European >99%. Canavan Disease - Gene: ASPA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000049:1-6. Detection Rate: Northern European 98%.

Carbamoylphosphate Synthetase I Deficiency - Gene: CPS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_001875:1-38. **Detection Rate**: Northern European >99%.

Carnitine Palmitoyltransferase IA Deficiency - Gene: CPT1A. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_001876:2-19. Detection Rate: Northern European >99%.

Carnitine Palmitoyltransferase II Deficiency - Gene: CPT2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000098:1-5. Detection Rate: Northern European >99%.

Cartilage-hair Hypoplasia - Gene: RMRP. Autosomal Recessive. Sequencing with copy number analysis. Exon: NR_003051:1. Detection Rate: Northern European

Cerebrotendinous Xanthomatosis - Gene: CYP27A1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000784:1-9. **Detection Rate:** Northern European >99%.

Citrullinemia Type 1 - Gene: ASS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000050:3-16. **Detection Rate**: Northern European >99%.

CLN3-related Neuronal Ceroid Lipofuscinosis - Gene: CLN3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_001042432:2-16. Detection Rate: Northern European >99%.

CLN5-related Neuronal Ceroid Lipofuscinosis - **Gene**: CLN5. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_006493:1-4. **Detection Rate**: Northern European >99%.

CLN6-related Neuronal Ceroid Lipofuscinosis - Gene: CLN6. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_017882:1-7. **Detection Rate**: Northern European >99%.

CLN8-related Neuronal Ceroid Lipofuscinosis - Gene: CLN8. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_018941:2-3. **Detection Rate:** Northern European >99%.

Cohen Syndrome - Gene: VPS13B. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_017890:2-62. Detection Rate: Northern European

COL4A3-related Alport Syndrome - Gene: COL4A3. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000091:1-52. **Detection Rate:** Northern European 97%.

COL4A4-related Alport Syndrome - Gene: COL4A4. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000092:2-48. **Detection Rate:** Northern European 98%.



RESU TS REC P ENT
SEATTLE SPERM BANK
Attn: Jeffrey Olliffe

NPI: 1306838271

Report Date: 08/02/2019

MA E

DONOR 10379

Ethnicity: Northern European Barcode: 11004212607604

FEMA E N/A

DONOR 10379
DOB:

Combined Pituitary Hormone Deficiency, PROP1-related - **Gene**: PROP1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_006261:1-3. **Detection Rate**: Northern European >99%.

Congenital Adrenal Hyperplasia, CYP21A2-related - Gene: CYP21A2. Autosomal Recessive. Analysis of homologous regions. Variants (13): CYP21A2 deletion, CYP21A2 duplication, CYP21A2 triplication, G111Vfs*21, I173N, L308Ffs*6, P31L, Q319*, Q319*+CYP21A2dup, R357W, V281L, [I237N;V238E;M240K], c.293-13C>G. Detection Rate: Northern European 96%.

Congenital Disorder of Glycosylation Type Ia - Gene: PMM2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000303:1-8. Detection Rate: Northern European >99%.

Congenital Disorder of Glycosylation Type Ic - Gene: ALG6. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_013339:2-15. Detection Rate: Northern European >99%.

Congenital Disorder of Glycosylation, MPI-related - Gene: MPI. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_002435:1-8. Detection Rate: Northern European >99%.

Costeff Optic Atrophy Syndrome - **Gene**: OPA3. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_025136:1-2. **Detection Rate**: Northern European >99%.

Cystic Fibrosis - **Gene**: CFTR. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000492:1-27. IVS8-5T allele analysis is only reported in the presence of the R117H mutation. **Detection Rate**: Northern European >99%. **Cystinosis** - **Gene**: CTNS. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_004937:3-12. **Detection Rate**: Northern European >99%.

D-bifunctional Protein Deficiency - Gene: HSD17B4. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000414:1-24. **Detection Rate**: Northern European 98%.

Delta-sarcoglycanopathy - **Gene**: SGCD. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000337:2-9. **Detection Rate**: Northern European 99%

Dihydrolipoamide Dehydrogenase Deficiency - Gene: DLD. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000108:1-14. **Detection Rate:** Northern European >99%.

Dysferlinopathy - **Gene:** DYSF. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_003494:1-55. **Detection Rate:** Northern European 98%.

Dystrophinopathy (Including Duchenne/Becker Muscular Dystrophy) - Gene: DMD. X-linked Recessive. Sequencing with copy number analysis. Exons: NM 004006:1-79. Detection Rate: Northern European >99%.

ERCC6-related Disorders - **Gene**: ERCC6. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000124:2-21. **Detection Rate**: Northern European 99%.

ERCC8-related Disorders - Gene: ERCC8. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000082:1-12. **Detection Rate:** Northern European 95%.

EVC-related Ellis-van Creveld Syndrome - **Gene**: EVC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_153717:1-21. **Detection Rate**: Northern European 96%.

EVC2-related Ellis-van Creveld Syndrome - Gene: EVC2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_147127:1-22. **Detection Rate**: Northern European >99%.

Fabry Disease - **Gene**: GLA. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM_000169:1-7. **Detection Rate**: Northern European 98%. **Familial Dysautonomia** - **Gene**: IKBKAP. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_003640:2-37. **Detection Rate**: Northern European >99%.

Familial Mediterranean Fever - Gene: MEFV. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000243:1-10. Detection Rate: Northern European >99%.

Fanconi Anemia Complementation Group A - **Gene**: FANCA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000135:1-43. **Detection Rate**: Northern European 92%.

Fanconi Anemia, FANCC-related - **Gene:** FANCC. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000136:2-15. **Detection Rate:** Northern European >99%.

FKRP-related Disorders - **Gene**: FKRP. Autosomal Recessive. Sequencing with copy number analysis. **Exon**: NM_024301:4. **Detection Rate**: Northern European >99%. **FKTN-related Disorders** - **Gene**: FKTN. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_001079802:3-11. **Detection Rate**: Northern European >99%

Galactokinase Deficiency - **Gene:** GALK1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000154:1-8. **Detection Rate:** Northern European >99%.

Galactosemia - **Gene**: GALT. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000155:1-11. **Detection Rate**: Northern European >99%. **Gamma-sarcoglycanopathy** - **Gene**: SGCG. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000231:2-8. **Detection Rate**: Northern European 88%.

Gaucher Disease - **Gene**: GBA. Autosomal Recessive. Analysis of homologous regions. **Variants (10)**: D409V, D448H, IVS2+1G>A, L444P, N370S, R463C, R463H, R496H, V394L, p.L29Afs*18. **Detection Rate**: Northern European 60%.

GJB2-related DFNB1 Nonsyndromic Hearing Loss and Deafness - Gene: GJB2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_004004:1-2. **Detection Rate**: Northern European >99%.

GLB1-related Disorders - **Gene**: GLB1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000404:1-16. **Detection Rate**: Northern European >99%.

GLDC-related Glycine Encephalopathy - **Gene**: GLDC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000170:1-25. **Detection Rate**: Northern European 94%.

Glutaric Acidemia, GCDH-related - Gene: GCDH. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000159:2-12. **Detection Rate**: Northern European >99%.

Glycogen Storage Disease Type Ia - **Gene:** G6PC. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000151:1-5. **Detection Rate:** Northern European >99%.

Glycogen Storage Disease Type Ib - Gene: SLC37A4. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_001164277:3-11. **Detection Rate**: Northern European >99%.

Glycogen Storage Disease Type III - Gene: AGL. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000642:2-34. **Detection Rate**: Northern European >99%.

GNE Myopathy - **Gene**: GNE. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_001128227:1-12. **Detection Rate**: Northern European >99%. **GNPTAB-related Disorders** - **Gene**: GNPTAB. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_024312:1-21. **Detection Rate**: Northern European >99%.

HADHA-related Disorders - **Gene**: HADHA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000182:1-20. **Detection Rate**: Northern European >99%.

Hb Beta Chain-related Hemoglobinopathy (Including Beta Thalassemia and Sickle Cell Disease) - Gene: HBB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000518:1-3. Detection Rate: Northern European >99%.

Hereditary Fructose Intolerance - **Gene**: ALDOB. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000035:2-9. **Detection Rate**: Northern European >99%.

Herlitz Junctional Epidermolysis Bullosa, LAMB3-related - Gene: LAMB3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000228:2-23. Detection Rate: Northern European >99%.

Hexosaminidase A Deficiency (Including Tay-Sachs Disease) - **Gene:** HEXA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000520:1-14. **Detection Rate:** Northern European >99%.

HMG-CoA Lyase Deficiency - Gene: HMGCL. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000191:1-9. Detection Rate: Northern European 98%

Holocarboxylase Synthetase Deficiency - Gene: HLCS. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000411:4-12. **Detection Rate**: Northern European >99%.

Homocystinuria, CBS-related - **Gene**: CBS. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000071:3-17. **Detection Rate**: Northern European >99%.

Hydrolethalus Syndrome - **Gene**: HYLS1. Autosomal Recessive. Sequencing with copy number analysis. **Exon**: NM_145014:4. **Detection Rate**: Northern European >99%.

Hypophosphatasia - **Gene:** ALPL. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000478:2-12. **Detection Rate:** Northern European >909%



RESU TS REC P ENT

SEATTLE SPERM BANK

Attn: Jeffrey Olliffe

NPI: 1306838271

Report Date: 08/02/2019

DONOR 10379 DOB:

MA E

FEMA E

N/A

Ethnicity: Northern European **Barcode:** 11004212607604

Isovaleric Acidemia - **Gene**: IVD. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_002225:1-12. **Detection Rate**: Northern European >99%.

Joubert Syndrome 2 - Gene: TMEM216. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_001173990:1-5. **Detection Rate:** Northern European >99%.

Junctional Epidermolysis Bullosa, LAMA3-related - Gene: LAMA3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000227:1-38. Detection Rate: Northern European >99%.

Junctional Epidermolysis Bullosa, LAMC2-related - Gene: LAMC2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_005562:1-23. Detection Rate: Northern European >99%.

KCNJ11-related Familial Hyperinsulinism - Gene: KCNJ11. Autosomal Recessive. Sequencing with copy number analysis. Exon: NM_000525:1. Detection Rate: Northern European >99%.

Krabbe Disease - **Gene**: GALC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000153:1-17. **Detection Rate**: Northern European >99%. **LAMA2-related Muscular Dystrophy** - **Gene**: LAMA2. Autosomal Recessive.

Sequencing with copy number analysis. Exons: NM_000426:1-65. Detection Rate: Northern European >99%.

Leigh Syndrome, French-Canadian Type - **Gene**: LRPPRC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_133259:1-38. **Detection Rate**: Northern European >99%.

Lipoid Congenital Adrenal Hyperplasia - Gene: STAR. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000349:1-7. **Detection Rate**: Northern European >99%.

Lysosomal Acid Lipase Deficiency - Gene: LIPA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000235:2-10. **Detection Rate**: Northern European >99%.

Maple Syrup Urine Disease Type Ia - **Gene:** BCKDHA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000709:1-9. **Detection Rate:** Northern European >99%.

Maple Syrup Urine Disease Type Ib - Gene: BCKDHB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_183050:1-10. Detection Rate: Northern European >99%.

Maple Syrup Urine Disease Type II - Gene: DBT. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_001918:1-11. **Detection Rate:** Northern European 96%.

Medium Chain Acyl-CoA Dehydrogenase Deficiency - Gene: ACADM. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000016:1-12. Detection Rate: Northern European >99%.

Megalencephalic Leukoencephalopathy with Subcortical Cysts - Gene: MLC1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_015166:2-12. Detection Rate: Northern European >99%.

Metachromatic Leukodystrophy - **Gene**: ARSA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000487:1-8. **Detection Rate**: Northern European >99%.

Methylmalonic Acidemia, cblA Type - **Gene**: MMAA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_172250:2-7. **Detection Rate**: Northern European >99%.

Methylmalonic Acidemia, cblB Type - **Gene**: MMAB. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_052845:1-9. **Detection Rate**: Northern European >99%.

Methylmalonic Aciduria and Homocystinuria, cblC Type - Gene: MMACHC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM 015506:1-4. Detection Rate: Northern European >99%.

MKS1-related Disorders - **Gene**: MKS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_017777:1-18. **Detection Rate**: Northern European >99%.

Mucolipidosis III Gamma - Gene: GNPTG. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_032520:1-11. **Detection Rate:** Northern European >99%.

Mucolipidosis IV - **Gene:** MCOLN1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_020533:1-14. **Detection Rate:** Northern European >99%.

Mucopolysaccharidosis Type I - **Gene**: IDUA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000203:1-14. **Detection Rate**: Northern European >99%.

Mucopolysaccharidosis Type II - Gene: IDS. X-linked Recessive. Sequencing with copy number analysis. **Exons:** NM_000202:1-9. **Detection Rate:** Northern European 88%.

Mucopolysaccharidosis Type IIIA - **Gene**: SGSH. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000199:1-8. **Detection Rate**: Northern European >99%.

Mucopolysaccharidosis Type IIIB - Gene: NAGLU. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000263:1-6. **Detection Rate**: Northern European >99%.

Mucopolysaccharidosis Type IIIC - **Gene:** HGSNAT. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_152419:1-18. **Detection Rate:** Northern European >99%.

MUT-related Methylmalonic Acidemia - **Gene**: MUT. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000255:2-13. **Detection Rate**: Northern European >99%.

MYO7A-related Disorders - **Gene**: MYO7A. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000260:2-49. **Detection Rate**: Northern European >99%.

NEB-related Nemaline Myopathy - **Gene:** NEB. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_001271208:3-80,117-183. **Detection Rate:** Northern European 92%.

Nephrotic Syndrome, NPHS1-related - **Gene**: NPHS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_004646:1-29. **Detection Rate**: Northern European >99%.

Nephrotic Syndrome, NPHS2-related - Gene: NPHS2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_014625:1-8. Detection Rate: Northern European >99%.

Niemann-Pick Disease Type C1 - **Gene:** NPC1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000271:1-25. **Detection Rate:** Northern European >99%.

Niemann-Pick Disease Type C2 - **Gene:** NPC2. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_006432:1-5. **Detection Rate:** Northern European >99%.

Niemann-Pick Disease, SMPD1-related - **Gene:** SMPD1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000543:1-6. **Detection Rate:** Northern European >99%.

Nijmegen Breakage Syndrome - **Gene**: NBN. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_002485:1-16. **Detection Rate**: Northern European >99%.

Ornithine Transcarbamylase Deficiency - Gene: OTC. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM_000531:1-10. **Detection Rate**: Northern European 97%.

PCCA-related Propionic Acidemia - **Gene**: PCCA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000282:1-24. **Detection Rate**: Northern European 95%.

PCCB-related Propionic Acidemia - **Gene**: PCCB. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000532:1-15. **Detection Rate**: Northern European >99%.

PCDH15-related Disorders - **Gene:** PCDH15. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_033056:2-33. **Detection Rate:** Northern European 93%.

Pendred Syndrome - **Gene**: SLC26A4. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000441:2-21. **Detection Rate**: Northern European >99%.

Peroxisome Biogenesis Disorder Type 1 - Gene: PEX1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000466:1-24. **Detection Rate**: Northern European >99%.

Peroxisome Biogenesis Disorder Type 3 - **Gene**: PEX12. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000286:1-3. **Detection Rate**: Northern European >99%.

Peroxisome Biogenesis Disorder Type 4 - Gene: PEX6. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000287:1-17. **Detection Rate**: Northern European 97%.

Peroxisome Biogenesis Disorder Type 5 - **Gene**: PEX2. Autosomal Recessive. Sequencing with copy number analysis. **Exon**: NM_000318:4. **Detection Rate**: Northern European >99%.

Peroxisome Biogenesis Disorder Type 6 - **Gene**: PEX10. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_153818:1-6. **Detection Rate**: Northern European >99%.



RESU TS REC P ENT

SEATTLE SPERM BANK

Attn: Jeffrey Olliffe

NPI: 1306838271

Report Date: 08/02/2019

MA E **DONOR 10379**

DOB: Ethnicity: Northern European Barcode: 11004212607604

FEMA E N/A

Phenylalanine Hydroxylase Deficiency - Gene: PAH. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000277:1-13. Detection Rate: Northern European >99%.

POMGNT-related Disorders - **Gene**: POMGNT1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_017739:2-22. **Detection Rate**: Northern European 96%.

Pompe Disease - **Gene**: GAA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000152:2-20. **Detection Rate**: Northern European 98%.

PPT1-related Neuronal Ceroid Lipofuscinosis - Gene: PPT1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000310:1-9. **Detection Rate**: Northern European >99%.

Primary Carnitine Deficiency - **Gene**: SLC22A5. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_003060:1-10. **Detection Rate**: Northern Furgnean >99%

Primary Hyperoxaluria Type 1 - **Gene**: AGXT. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000030:1-11. **Detection Rate**: Northern European >99%.

Primary Hyperoxaluria Type 2 - Gene: GRHPR. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_012203:1-9. **Detection Rate:** Northern European >99%.

Primary Hyperoxaluria Type 3 - Gene: HOGA1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_138413:1-7. **Detection Rate**: Northern European >99%.

Pycnodysostosis - **Gene:** CTSK. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000396:2-8. **Detection Rate:** Northern European >99%.

Pyruvate Carboxylase Deficiency - Gene: PC. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000920:3-22. **Detection Rate:** Northern European >99%.

Rhizomelic Chondrodysplasia Punctata Type 1 - Gene: PEX7. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000288:1-10. Detection Rate: Northern European >99%.

RTEL1-related Disorders - **Gene**: RTEL1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_032957:2-35. **Detection Rate**: Northern European >99%.

Salla Disease - Gene: SLC17A5. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_012434:1-11. Detection Rate: Northern European 98%.

Sandhoff Disease - Gene: HEXB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000521:1-14. Detection Rate: Northern European >99%.

Short-chain Acyl-CoA Dehydrogenase Deficiency - Gene: ACADS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000017:1-10. Detection Rate: Northern European >99%.

Sjogren-Larsson Syndrome - **Gene**: ALDH3A2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000382:1-10. **Detection Rate**: Northern European 96%.

SLC26A2-related Disorders - Gene: SLC26A2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000112:2-3. **Detection Rate**: Northern European >99%.

Smith-Lemli-Opitz Syndrome - Gene: DHCR7. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_001360:3-9. Detection Rate: Northern European >99%.

Spastic Paraplegia Type 15 - **Gene**: ZFYVE26. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_015346:2-42. **Detection Rate**: Northern European >99%.

Spinal Muscular Atrophy - Gene: SMN1. Autosomal Recessive. Spinal muscular atrophy. Variant (1): SMN1 copy number. Detection Rate: Northern European 95%.

Spondylothoracic Dysostosis - **Gene**: MESP2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_001039958:1-2. **Detection Rate**: Northern European >99%.

TGM1-related Autosomal Recessive Congenital Ichthyosis - **Gene**: TGM1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000359:2-15. **Detection Rate**: Northern European >99%.

TPP1-related Neuronal Ceroid Lipofuscinosis - Gene: TPP1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000391:1-13. **Detection Rate**: Northern European >99%.

Tyrosine Hydroxylase Deficiency - Gene: TH. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_199292:1-14. **Detection Rate**: Northern European >99%.

Tyrosinemia Type I - Gene: FAH. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000137:1-14. **Detection Rate:** Northern European >99%.

Tyrosinemia Type II - **Gene:** TAT. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000353:2-12. **Detection Rate:** Northern European >99%.

USH1C-related Disorders - **Gene**: USH1C. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_005709:1-21. **Detection Rate**: Northern European >99%.

USH2A-related Disorders - **Gene:** USH2A. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_206933:2-72. **Detection Rate:** Northern European 94%.

Usher Syndrome Type 3 - **Gene:** CLRN1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_174878:1-3. **Detection Rate:** Northern European >99%

Very-long-chain Acyl-CoA Dehydrogenase Deficiency - **Gene**: ACADVL. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000018:1-20. **Detection Rate**: Northern European >99%.

Wilson Disease - Gene: ATP7B. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000053:1-21. Detection Rate: Northern European >99%.

X-linked Adrenoleukodystrophy - Gene: ABCD1. X-linked Recessive. Sequencing with copy number analysis. Exons: NM_000033:1-6. Detection Rate: Northern European 77%.

X-linked Alport Syndrome - **Gene**: COL4A5. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM_000495:1-51. **Detection Rate**: Northern European 95%.

X-linked Congenital Adrenal Hypoplasia - Gene: NR0B1. X-linked Recessive. Sequencing with copy number analysis. Exons: NM_000475:1-2. Detection Rate: Northern European 99%.

X-linked Juvenile Retinoschisis - Gene: RS1. X-linked Recessive. Sequencing with copy number analysis. Exons: NM_000330:1-6. Detection Rate: Northern European 98%

X-linked Myotubular Myopathy - **Gene:** MTM1. X-linked Recessive. Sequencing with copy number analysis. **Exons:** NM_000252:2-15. **Detection Rate:** Northern European 98%.

X-linked Severe Combined Immunodeficiency - **Gene:** IL2RG. X-linked Recessive. Sequencing with copy number analysis. **Exons:** NM_000206:1-8. **Detection Rate:** Northern European >99%.

Xeroderma Pigmentosum Group A - **Gene:** XPA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000380:1-6. **Detection Rate:** Northern European >99%.

Xeroderma Pigmentosum Group C - **Gene**: XPC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_004628:1-16. **Detection Rate**: Northern European 97%.



MA E

DONOR 10379

DOB:

Ethnicity: Northern European Barcode: 11004212607604

FEMA E N/A

Risk Calculations

Below are the risk calculations for all conditions tested. Since negative results do not completely rule out the possibility of being a carrier, the **residual risk** represents the patient's post-test likelihood of being a carrier and the **reproductive risk** represents the likelihood the patient's future children could inherit each disease. These risks are inherent to all carrier screening tests, may vary by ethnicity, are predicated on a negative family history and are present even after a negative test result. Inaccurate reporting of ethnicity may cause errors in risk calculation. The reproductive risk presented is based on a hypothetical pairing with a partner of the same ethnic group.

Disease	DONOR 10379 Residual Risk	Reproductive Risk
11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia	1 in 3,800	< 1 in 1,000,000
6-pyruvoyl-tetrahydropterin Synthase Deficiency	< 1 in 50,000	< 1 in 1,000,000
ABCC8-related Familial Hyperinsulinism	1 in 17,000	< 1 in 1,000,000
Adenosine Deaminase Deficiency	1 in 22,000	< 1 in 1,000,000
Alpha Thalassemia	Alpha globin status: aa/aa.	Not calculated
Alpha-mannosidosis	1 in 35,000	< 1 in 1,000,000
Alpha-sarcoglycanopathy	1 in 45,000	< 1 in 1,000,000
Alstrom Syndrome	< 1 in 50,000	< 1 in 1,000,000
MT-related Glycine Encephalopathy	1 in 22,000	< 1 in 1,000,000
Indermann Syndrome	< 1 in 50,000	< 1 in 1,000,000
rgininemia	< 1 in 17,000	< 1 in 1,000,000
•		
rgininosuccinic Aciduria	1 in 13,000	< 1 in 1,000,000
spartylglucosaminuria	< 1 in 50,000	< 1 in 1,000,000
staxia with Vitamin E Deficiency	< 1 in 50,000	< 1 in 1,000,000
taxia-telangiectasia	1 in 11,000	< 1 in 1,000,000
TP7A-related Disorders	< 1 in 1,000,000	1 in 600,000
utoimmune Polyglandular Syndrome Type 1	1 in 15,000	< 1 in 1,000,000
utosomal Recessive Osteopetrosis Type 1	1 in 35,000	< 1 in 1,000,000
utosomal Recessive Polycystic Kidney Disease, PKHD1-related	1 in 8,100	< 1 in 1,000,000
utosomal Recessive Spastic Ataxia of Charlevoix-Saguenay	< 1 in 44,000	< 1 in 1,000,000
ardet-Biedl Syndrome, BBS1-related	1 in 32,000	< 1 in 1,000,000
ardet-Biedl Syndrome, BBS10-related	1 in 42,000	< 1 in 1,000,000
ardet-Biedl Syndrome, BBS12-related	< 1 in 50,000	< 1 in 1,000,000
ardet-Biedl Syndrome, BBS2-related	< 1 in 50,000	< 1 in 1,000,000
CS1L-related Disorders	< 1 in 50,000	< 1 in 1,000,000
eta-sarcoglycanopathy	1 in 39,000	< 1 in 1,000,000
iotinidase Deficiency	1 in 13,000	1 in 650,000
loom Syndrome	< 1 in 50,000	< 1 in 1,000,000
alpainopathy	1 in 13,000	< 1 in 1,000,000
anavan Disease	1 in 9,700	< 1 in 1,000,000
arbamoylphosphate Synthetase I Deficiency	< 1 in 57,000	< 1 in 1,000,000
arnitine Palmitoyltransferase IA Deficiency	< 1 in 50,000	< 1 in 1,000,000
arnitine Palmitoyltransferase II Deficiency	1 in 25,000	< 1 in 1,000,000
artilage-hair Hypoplasia	< 1 in 50,000	< 1 in 1,000,000
erebrotendinous Xanthomatosis	1 in 11,000	< 1 in 1,000,000
itrullinemia Type 1	1 in 14,000	< 1 in 1,000,000
LN3-related Neuronal Ceroid Lipofuscinosis	1 in 8,600	< 1 in 1,000,000
LN5-related Neuronal Ceroid Lipofuscinosis	< 1 in 50,000	< 1 in 1,000,000
LN6-related Neuronal Ceroid Lipofuscinosis	1 in 43,000	< 1 in 1,000,000
LN8-related Neuronal Ceroid Lipofuscinosis	< 1 in 50,000	< 1 in 1,000,000
ohen Syndrome	< 1 in 15,000	< 1 in 1,000,000
OL4A3-related Alport Syndrome	1 in 6,200	< 1 in 1,000,000
OL4A4-related Alport Syndrome	1 in 12,000	< 1 in 1,000,000
ombined Pituitary Hormone Deficiency, PROP1-related	1 in 6,100	< 1 in 1,000,000
ongenital Adrenal Hyperplasia, CYP21A2-related	1 in 1,300	1 in 280,000
ongenital Disorder of Glycosylation Type Ia	1 in 16,000	< 1 in 1,000,000
ongenital Disorder of Glycosylation Type Ic	< 1 in 50,000	< 1 in 1,000,000
Congenital Disorder of Glycosylation Type IC	< 1 in 50,000 < 1 in 50,000	< 1 in 1,000,000 < 1 in 1,000,000
• • • •		< 1 in 1,000,000 < 1 in 1,000,000
Costeff Optic Atrophy Syndrome	< 1 in 50,000	
Cystic Fibrosis	1 in 3,000	1 in 360,000



MA E **DONOR 10379**

DOB: Ethnicity: Northern European Barcode: 11004212607604

FEMA E N/A

Disease	DONOR 10379 Residual Risk	Reproductive Risk
Cystinosis	1 in 22.000	< 1 in 1,000,000
D-bifunctional Protein Deficiency	1 in 9,000	< 1 in 1,000,000
Delta-sarcoglycanopathy	< 1 in 40,000	< 1 in 1,000,000
Dihydrolipoamide Dehydrogenase Deficiency	< 1 in 50,000	< 1 in 1,000,000
Dysferlinopathy	1 in 11,000	< 1 in 1,000,000
Dystrophinopathy (Including Duchenne/Becker Muscular Dystrophy)	Not calculated	Not calculated
ERCC6-related Disorders	1 in 26,000	< 1 in 1,000,000
ERCC8-related Disorders	< 1 in 9,900	< 1 in 1,000,000
EVC-related Ellis-van Creveld Syndrome	1 in 7,500	< 1 in 1,000,000
EVC2-related Ellis-van Creveld Syndrome	< 1 in 50,000	< 1 in 1,000,000
Fabry Disease	< 1 in 1,000,000	1 in 80,000
Familial Dysautonomia Familial Mediterranean Fever	< 1 in 50,000 < 1 in 50,000	< 1 in 1,000,000 < 1 in 1,000,000
Fanconi Anemia Complementation Group A	1 in 2,800	< 1 in 1,000,000
Fanconi Anemia, FANCC-related	< 1 in 50,000	< 1 in 1,000,000
FKRP-related Disorders	1 in 16,000	< 1 in 1,000,000
FKTN-related Disorders	< 1 in 50,000	< 1 in 1,000,000
Galactokinase Deficiency	1 in 10,000	< 1 in 1,000,000
Galactosemia	1 in 8,600	< 1 in 1,000,000
Gamma-sarcoglycanopathy	1 in 3,000	< 1 in 1,000,000
Gaucher Disease	1 in 260	1 in 110,000
GJB2-related DFNB1 Nonsyndromic Hearing Loss and Deafness	1 in 2,500	1 in 260,000
GLB1-related Disorders	1 in 19,000	< 1 in 1,000,000
GLDC-related Glycine Encephalopathy	1 in 2,800	< 1 in 1,000,000
Glutaric Acidemia, GCDH-related	1 in 16,000	< 1 in 1,000,000
Glycogen Storage Disease Type Ia	1 in 18,000	< 1 in 1,000,000
Glycogen Storage Disease Type Ib	1 in 35,000	< 1 in 1,000,000
Glycogen Storage Disease Type III	1 in 16,000	< 1 in 1,000,000
GNE Myopathy GNPTAB-related Disorders	1 in 23,000	< 1 in 1,000,000
HADHA-related Disorders	1 in 32,000 1 in 20,000	< 1 in 1,000,000 < 1 in 1,000,000
Hb Beta Chain-related Hemoglobinopathy (Including Beta Thalassemia and	1 111 20,000	< 1 111 1,000,000
Sickle Cell Disease)	1 in 3,100	1 in 390,000
Hereditary Fructose Intolerance	1 in 7,900	< 1 in 1,000,000
Herlitz Junctional Epidermolysis Bullosa, LAMB3-related	< 1 in 50,000	< 1 in 1,000,000
Hexosaminidase A Deficiency (Including Tay-Sachs Disease)	1 in 30,000	< 1 in 1,000,000
HMG-CoA Lyase Deficiency	< 1 in 33,000	< 1 in 1,000,000
Holocarboxylase Synthetase Deficiency	1 in 15,000	< 1 in 1,000,000
Homocystinuria, CBS-related	1 in 9,400	< 1 in 1,000,000
Hydrolethalus Syndrome	< 1 in 50,000	< 1 in 1,000,000
Hypophosphatasia	1 in 27,000	< 1 in 1,000,000
Isovaleric Acidemia Joubert Syndrome 2	1 in 32,000	< 1 in 1,000,000
Junctional Epidermolysis Bullosa, LAMA3-related	< 1 in 50,000 < 1 in 50,000	< 1 in 1,000,000 < 1 in 1,000,000
Junctional Epidermolysis Bullosa, LAMC2-related	< 1 in 50,000	< 1 in 1,000,000
KCNJ11-related Familial Hyperinsulinism	< 1 in 50,000	< 1 in 1,000,000
Krabbe Disease	1 in 14,000	< 1 in 1,000,000
LAMA2-related Muscular Dystrophy	1 in 34,000	< 1 in 1,000,000
Leigh Syndrome, French-Canadian Type	< 1 in 50,000	< 1 in 1,000,000
Lipoid Congenital Adrenal Hyperplasia	< 1 in 50,000	< 1 in 1,000,000
Lysosomal Acid Lipase Deficiency	1 in 18,000	< 1 in 1,000,000
Maple Syrup Urine Disease Type Ia	1 in 42,000	< 1 in 1,000,000
Maple Syrup Urine Disease Type Ib	1 in 39,000	< 1 in 1,000,000
Maple Syrup Urine Disease Type II	1 in 13,000	< 1 in 1,000,000
Medium Chain Acyl-CoA Dehydrogenase Deficiency	1 in 4,400	1 in 790,000
Megalencephalic Leukoencephalopathy with Subcortical Cysts	< 1 in 50,000	< 1 in 1,000,000
Metachromatic Leukodystrophy Methylmalonic Acidemia, chlA Tyne	1 in 16,000	< 1 in 1,000,000
Methylmalonic Acidemia, cblA Type Methylmalonic Acidemia, cblB Type	< 1 in 50,000 1 in 48,000	< 1 in 1,000,000 < 1 in 1,000,000
Methylmalonic Aciduria and Homocystinuria, cblC Type	1 in 16,000	< 1 in 1,000,000
MKS1-related Disorders	< 1 in 50,000	< 1 in 1,000,000
Mucolipidosis III Gamma	< 1 in 50,000	< 1 in 1,000,000 < 1 in 1,000,000
	50,000	1 111 1,000,000



MA E **DONOR 10379**

DOB: Ethnicity: Northern European Barcode: 11004212607604

FEMA E N/A

Residual Risk < 1 in 50,000 1 in 16,000 1 in 600,000 1 in 12,000 1 in 25,000 1 in 37,000 1 in 26,000	Risk <1 in 1,000,000 <1 in 1,000,000 1 in 150,000 <1 in 1,000,000
1 in 16,000 1 in 600,000 1 in 12,000 1 in 25,000 1 in 37,000	< 1 in 1,000,000 1 in 150,000 < 1 in 1,000,000
1 in 600,000 1 in 12,000 1 in 25,000 1 in 37,000	1 in 150,000 < 1 in 1,000,000
1 in 25,000 1 in 37,000	
1 in 37,000	
	< 1 in 1,000,000
1 in 26 000	< 1 in 1,000,000
1 111 20,000	< 1 in 1,000,000
1 in 15,000	< 1 in 1,000,000
1 in 1,200	1 in 400,000
< 1 in 50,000	< 1 in 1,000,000
1 in 35,000	< 1 in 1,000,000
1 in 19,000	< 1 in 1,000,000
< 1 in 50,000	< 1 in 1,000,000
1 in 25,000	< 1 in 1,000,000
1 in 16,000	< 1 in 1,000,000
< 1 in 1,000,000	1 in 140,000
1 in 4,200	< 1 in 1,000,000
1 in 22,000	< 1 in 1,000,000
1 in 3,300	< 1 in 1,000,000
1 in 8,200	< 1 in 1,000,000
	< 1 in 1,000,000
	< 1 in 1,000,000
	< 1 in 1,000,000
·	< 1 in 1,000,000
	< 1 in 1,000,000
	1 in 940,000
	< 1 in 1,000,000
	< 1 in 1,000,000 < 1 in 1,000,000
	< 1 in 1,000,000
	< 1 in 1,000,000
·	< 1 in 1,000,000
	< 1 in 1,000,000
Negative for g.27134T>G SNP	
SMN1: 2 copies	1 in 110,000
1 in 770	
< 1 in 50,000	< 1 in 1,000,000
1 in 22,000	< 1 in 1,000,000
1 in 30,000	< 1 in 1,000,000
< 1 in 50,000	< 1 in 1,000,000
1 in 16,000	< 1 in 1,000,000
1 in 25,000	< 1 in 1,000,000
1 in 35,000	< 1 in 1,000,000
1 in 2,200	< 1 in 1,000,000
1 in 41,000	< 1 in 1,000,000
1 in 18,000	< 1 in 1,000,000
1 in 8,600	< 1 in 1,000,000
1 in 90,000	1 in 42,000
Not calculated	Not calculated
< 1 in 1,000,000	< 1 in 1,000,000 1 in 40,000
	1 in 15,000 1 in 1,200 <1 in 50,000 1 in 35,000 1 in 19,000 <1 in 50,000 1 in 25,000 1 in 10,000 0 1 in 1,000,000 1 in 4,200 1 in 22,000 1 in 16,000 1 in 8,200 1 in 16,000 1 in 4,000 1 in 9,300 <1 in 71,000 <1 in 71,000 <1 in 10,000 1 in 4,000 1 in 4,000 1 in 4,000 1 in 1,000 <1 in 50,000 1 in 1,000 1 in 50,000 1 in 1,000 1 in 1,000



MA E **DONOR 10379**

DOB: Ethnicity: Northern European Barcode: 11004212607604

FEMA E N/A

Disease	DONOR 10379 Residual Risk	Reproductive Risk
X-linked Myotubular Myopathy	Not calculated	Not calculated
X-linked Severe Combined Immunodeficiency	< 1 in 1,000,000	1 in 200,000
Xeroderma Pigmentosum Group A	< 1 in 50,000	< 1 in 1,000,000
Xeroderma Pigmentosum Group C	1 in 7,300	< 1 in 1,000,000